Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 8Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Metastatic gpNMB Expressing Triple Negative Breast Cancer 1

Interventions

3-Iodobenzylguanidine 9Cyclophosphamide 6Amifampridine 6nilotinib 5fludarabine 5Magnetic Resonance Spectroscopy 5trametinib 4pembrolizumab 4gallium 68 PSMA-11 4fludarabine phosphate 4elotuzumab 4dabrafenib 4Nivolumab 4Bortezomib 4Afatinib 4venetoclax 3regorafenib 3midostaurin 3TIC10 compound 3Sunitinib 3Prednisone 3Lenalidomide 3Ipilimumab 3Everolimus 3Dexamethasone 3Crizotinib 3Capecitabine 3Axitinib 3Alpelisib 3Abiraterone Acetate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × glembatumumab vedotin × Clear all
NCT03067935 2018-05-21

Individual Patient Expanded Access-Glembatumumab Vedotin

Celldex Therapeutics

No longer available
Breast

Metastatic gpNMB Expressing Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡